Table 3 The comparisons of complement component in the pMN patients with or without anti-PLA2R antibodies
From: Complement activation products in the circulation and urine of primary membranous nephropathy
|  | PLA2R-Ab (+) (n = 91) | PLA2R-Ab (−) (n = 43) | Healthy controls |
|---|---|---|---|
P-C1q | 0.8 (0.6–1.1) | 0.7 (0.5–0.9) | 0.7 (0.5–0.9) |
P-C4d | 0.2 (0.2–0.3) ** | 0.2 (0.1–0.2) ** | 0.02 (0.01–0.02) |
P-MBL | 19.8 (6.7–38.3) | 19.5 (2.5–32.7) | 16.3 (6.8–23.8) |
P-Bb | 0.01 (0.01–0.01) ** | 0.01 (0.00–0.01) ** | 0.01 (0.00–0.01) |
P-Properdin | 0.2 (0.2–0.3) | 0.2 (0.1–0.2) | 0.2 (0.1–0.3) |
P-C3a | 79.5 (11.8–118) ** | 88.1 (10.3–127.8) ** | 0.9 (0.4–1.5) |
P-C5a | 3.7 (0.3–23.9) ** | 1.8 (0.3–23.8) ** | 0.06 (0.03–0.11) |
P-MAC | 2.6 (1.6–3.7) | 2.3 (1.2–4.0) | 2.5 (1.5–3.3) |
U-C1q | 0.00 (0.00–0.02) ** | 0.00 (0.00–0.23) ** | 1.11 (0.04–2.8) |
U-C4d | 0.05 (0.00–0.89) * | 0.02 (0.00–0.019) | 0.00 (0.00–0.07) |
U-MBL | 0.00 (0.00–0.00) | 0.0 (0.0–0.0) | 0.00 (0.00–0.00) |
U-Bb | 0.7 (0.0–1.6) ** | 0.9 (0.2–1.8) ** | 2.5 (1.7–4.6) |
U-Properdin | 0.0 (0.0–7.9) * | 0.0 (0.0–2.2) | 0.0 (0.0–0.0) |
U-C3a | 12.5 (2.4–36.7) ** | 21.1 (8.6–42.7) ** | 3.7 (1.6–5.8) |
U-C5a | 4.9 (0.0–30.3) * | 1.5 (0.0–11.0) | 3.3 (1.5–6.5) |
U-MAC | 0.6 (0.0–2.0) ** | 0.38 (0.05–3.26) ** | 0.0 (0.0–0.1) |